Settings for use of a rheumatoid arthritis flare measure4.
| Clinical Trials |
| Detecting adequacy of dose/regimen for duration of therapeutic effect — driving to remission (“tight control”) |
| Aiding dose/regimen optimization — titration and tapering while maintaining remission |
| Assessing effect of concomitant medications to control oscillating symptoms/signs |
| Assessing and reporting of episodic disease-worsening as an adverse event |
| Determining remission as absence of disease flare among other measures |
| Clinical Practice |
| Facilitating MD-patient communication when considering change in therapy for intermittent disease-worsening |
| Determining need to change treatment |
| Assessing patient-specific interventions to control episodic worsening |
| Enabling assessments to apply “tight control” strategies on an individual patient basis |
| Assessing episodic disease-worsening |
| Limiting effect of and disability associated with periodic disease-worsening (e.g., time lost from work) |